(384) Development of a solid lipid nanoparticle platform for the delivery of vancomycin

Currently the only use for orally delivered vancomycin (VCM) in in the treatment of C. diff infections of the colon (1). Overcoming this issue to provide an option to deliver VCM orally with an increased bioavailability would have significant implications in patient compliance and cost effectiveness of treatments of systemic infections, particularly of resistant bacteria such as methicillin resistant S. aureus (MRSA) (2). Solid lipid nanoparticles offer the potential to protect and traffick drugs allowing them to reach circulation via the oral route rather than intravenous administration (3).